Shire plc (NASDAQ:SHPG) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shire plc	N/A	0.00	N/A	7.94	21.44
Progenics Pharmaceuticals Inc.	16.27M	23.90	55.62M	-0.78	0.00

Demonstrates Shire plc and Progenics Pharmaceuticals Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows Shire plc and Progenics Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Shire plc	0.00%	13%	7.2%
Progenics Pharmaceuticals Inc.	-341.86%	-73.7%	-36.4%

Volatility & Risk

Shire plc has a 0.99 beta, while its volatility is 1.00%, thus making it less volatile than Standard and Poor’s 500. From a competition point of view, Progenics Pharmaceuticals Inc. has a 2.66 beta which is 166.00% more volatile compared to Standard and Poor’s 500.

Liquidity

Shire plc’s Current Ratio is 0.9 while its Quick Ratio is 0.5. On the competitive side is, Progenics Pharmaceuticals Inc. which has a 9.5 Current Ratio and a 9.5 Quick Ratio. Progenics Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Shire plc.

Dividends

Shire plc shareholders receive an annual dividend of $0.35 per share which is subject to 0.2% dividend yield. No dividend is paid out for Progenics Pharmaceuticals Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Shire plc and Progenics Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Shire plc	0	1	0	2.00
Progenics Pharmaceuticals Inc.	0	0	1	3.00

Shire plc’s consensus price target is $196, while its potential upside is 9.38%. Meanwhile, Progenics Pharmaceuticals Inc.’s consensus price target is $6.5, while its potential upside is 41.30%. Based on the analysts opinion we can conclude, Progenics Pharmaceuticals Inc. is looking more favorable than Shire plc.

Insider & Institutional Ownership

Institutional investors held 22.9% of Shire plc shares and 89.8% of Progenics Pharmaceuticals Inc. shares. Insiders held roughly 0.1% of Shire plc’s shares. On the other hand, insiders held about 0.4% of Progenics Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Shire plc	-3.11%	-5.99%	1.27%	6.01%	18.67%	9.67%
Progenics Pharmaceuticals Inc.	-16.38%	-22.64%	-41.43%	-50.63%	-27.42%	-27.06%

For the past year Shire plc had bullish trend while Progenics Pharmaceuticals Inc. had bearish trend.

Summary

Shire plc beats Progenics Pharmaceuticals Inc. on 8 of the 13 factors.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.